IL153543A0 - PHARMACEUTICAL COMPOSITIONS CONTAINING A COMPOUND WHICH INHIBITS OR MODULATES PPARdelta (beta) ACTIVITY - Google Patents

PHARMACEUTICAL COMPOSITIONS CONTAINING A COMPOUND WHICH INHIBITS OR MODULATES PPARdelta (beta) ACTIVITY

Info

Publication number
IL153543A0
IL153543A0 IL15354301A IL15354301A IL153543A0 IL 153543 A0 IL153543 A0 IL 153543A0 IL 15354301 A IL15354301 A IL 15354301A IL 15354301 A IL15354301 A IL 15354301A IL 153543 A0 IL153543 A0 IL 153543A0
Authority
IL
Israel
Prior art keywords
ppardelta
modulates
inhibits
beta
activity
Prior art date
Application number
IL15354301A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL153543A0 publication Critical patent/IL153543A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL15354301A 2000-07-20 2001-07-19 PHARMACEUTICAL COMPOSITIONS CONTAINING A COMPOUND WHICH INHIBITS OR MODULATES PPARdelta (beta) ACTIVITY IL153543A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21995600P 2000-07-20 2000-07-20
PCT/US2001/022819 WO2002007765A2 (fr) 2000-07-20 2001-07-19 Regulations de ppar$g(d)($g(b)) et leur utilisation en vue de traiter l'obesite et la resistance a l'insuline

Publications (1)

Publication Number Publication Date
IL153543A0 true IL153543A0 (en) 2003-07-06

Family

ID=22821422

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15354301A IL153543A0 (en) 2000-07-20 2001-07-19 PHARMACEUTICAL COMPOSITIONS CONTAINING A COMPOUND WHICH INHIBITS OR MODULATES PPARdelta (beta) ACTIVITY

Country Status (8)

Country Link
US (2) US6677298B2 (fr)
EP (1) EP1305046A2 (fr)
JP (1) JP2004531454A (fr)
AU (2) AU7792601A (fr)
CA (1) CA2417005A1 (fr)
IL (1) IL153543A0 (fr)
MX (1) MXPA03000508A (fr)
WO (1) WO2002007765A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020112256A1 (en) * 2000-12-11 2002-08-15 Allen Keith D. Transgenic mice containing proliferator-activated receptor gene disruptions
AU2002243778A1 (en) * 2001-02-02 2002-09-19 Smithkline Beecham Corporation Treatment of ppar mediated diseases
US20040242459A1 (en) * 2001-06-11 2004-12-02 Forrest Michael J Method for treating inflammatory diseases by administering a ppar-delta agonist
KR100693528B1 (ko) * 2004-10-29 2007-03-14 주식회사 팬택 전원 지연 인가 기능을 가지는 무선통신 단말기
JP5864077B2 (ja) 2006-09-08 2016-02-17 ロード アイランド ホスピタル アルコール誘発性肝疾患の治療、予防および回復
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US8483830B2 (en) * 2008-04-04 2013-07-09 Enteromedics Inc. Methods and systems for glucose regulation
JP5753784B2 (ja) 2008-10-10 2015-07-22 ダラ・バイオサイエンシズ，インコーポレイテッド スピカマイシン誘導体を用いて疼痛を治療又は予防する方法
WO2015061481A1 (fr) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Méthodes de traitement de tumeurs liquides à l'aide de compositions comprenant des dérivés de spicamycine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5861274A (en) 1990-03-22 1999-01-19 The Salk Institute For Biological Studies Nucleic acids encoding peroxisome proliferator-activated receptor
AU2579692A (en) 1991-09-17 1993-04-27 Salk Institute For Biological Studies, The Receptor of the thyroid/steroid hormone receptor superfamily
US5570696A (en) * 1994-01-26 1996-11-05 Cambridge Heart, Inc. Method and apparatus for assessing myocardial electrical stability
WO1997010813A1 (fr) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Antagonistes de ppar gamma pour le traitement de l'obesite
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
GB9917405D0 (en) 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method

Also Published As

Publication number Publication date
CA2417005A1 (fr) 2002-01-31
US6677298B2 (en) 2004-01-13
WO2002007765A3 (fr) 2003-01-30
AU7792601A (en) 2002-02-05
JP2004531454A (ja) 2004-10-14
MXPA03000508A (es) 2003-10-06
WO2002007765A2 (fr) 2002-01-31
AU2001277926B2 (en) 2006-02-16
US20040106538A1 (en) 2004-06-03
EP1305046A2 (fr) 2003-05-02
US20020042359A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
IL149138A0 (en) Pharmaceutical compositions containing metformin
IL187605A0 (en) Pharmaceutical compositions containing (-) (3-trihalomethylphenoxy) (4-halophenyl)
IL148357A0 (en) Pharmaceutical compositions containing a benzamide derivative
PL351551A1 (en) Synergistic insecticidal compositions
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
IL148864A (en) Pharmaceutical compositions containing nimesulide
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
IL139210A0 (en) A pharmaceutical composition containing a macrolide compound
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
MXPA03000387A (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina-1.
IL123143A0 (en) Pharmaceutical compositions containing mupirocin
IL146434A0 (en) Pharmaceutical compositions containing ecteinascidin 743
HUP0202255A2 (en) Crystalline 1-methylcarbapenem compounds and pharmaceutical compositions containing them
IL153907A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 2-METHYLENE-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3
EP1145707A4 (fr) Compositions destinees a un usage externe
IL137505A0 (en) Pharmaceutical compositions containing tramadol
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
HUP0105443A3 (en) Pharmaceutical compositions containing spisulosine compounds having antitumour activity
HUP0102894A3 (en) A substituted triazolo-pyridazine derivative, pharmaceutical compositions containing them
HUP0200747A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
IL153543A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A COMPOUND WHICH INHIBITS OR MODULATES PPARdelta (beta) ACTIVITY
IL135178A0 (en) Pesticidal compositions
IL148169A0 (en) Pharmaceutical compositions containing a benzamide derivative
IL125244A0 (en) Pharmaceutical compositions containing low-melting waxes